TriSalus Life Sciences, Inc.
TLSI
$4.73
$0.368.24%
NASDAQ
| 03/31/2026 | 12/31/2025 | 09/30/2025 | 06/30/2025 | 03/31/2025 | |
|---|---|---|---|---|---|
| Net Income | 114.83% | 3.51% | -350.65% | -91.32% | 21.44% |
| Total Depreciation and Amortization | -21.51% | -34.72% | -10.44% | -14.95% | -1.71% |
| Total Amortization of Deferred Charges | 25.96% | 58.43% | 64.67% | -3.75% | -- |
| Total Other Non-Cash Items | -325.99% | 107.44% | 175.78% | 160.99% | 46.20% |
| Change in Net Operating Assets | -81.49% | -213.49% | 175.71% | 78.24% | 431.06% |
| Cash from Operations | -44.03% | 56.47% | 65.81% | 45.46% | 58.60% |
| Capital Expenditure | 81.30% | 18.00% | -27.81% | 255.00% | -1,042.42% |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | -- | -- | -- | -- | -- |
| Cash from Investing | 80.25% | 18.00% | -4.14% | 255.00% | -981.82% |
| Total Debt Issued | -- | -- | -- | -100.00% | -- |
| Total Debt Repaid | 87.32% | 84.21% | 72.73% | 95.24% | -222.73% |
| Issuance of Common Stock | 15,189.25% | -90.71% | -98.49% | 517.33% | -91.14% |
| Repurchase of Common Stock | -- | -- | -- | -- | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | 49.42% | -- | -- | 40.26% | -- |
| Cash from Financing | 337.50% | -90.75% | -98.59% | -20.30% | 209.92% |
| Foreign Exchange rate Adjustments | -- | -- | -- | -- | -- |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | 699.20% | 18.64% | 26.77% | 7.83% | 157.32% |